Skip to main content

Travere Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, March 28, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming conferences:

Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days
Tuesday, April 4, 2023, at 3:55 p.m. ET

BofA Securities 2023 Health Care Conference
Wednesday, May 10, 2023, at 3:40 p.m. PT

Live webcasts of the presentations will be accessible on the Investor page of Travere’s website at ir.travere.com/events-presentations. Replays will be available for up to 30 days following each event.

About Travere Therapeutics

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.

Media:
Nivi Nehra
Vice President, Corporate Communications
888-969-7879                                  
mediarelations@travere.com
Investors:
Naomi Eichenbaum
Vice President, Investor Relations
888-969-7879                                                          
IR@travere.com

Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  224.21
+0.00 (0.00%)
AAPL  262.82
+0.00 (0.00%)
AMD  252.92
+0.00 (0.00%)
BAC  52.57
+0.00 (0.00%)
GOOG  260.51
+0.00 (0.00%)
META  738.36
+0.00 (0.00%)
MSFT  523.61
+0.00 (0.00%)
NVDA  186.26
+0.00 (0.00%)
ORCL  283.33
+0.00 (0.00%)
TSLA  433.72
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.